All Trials

A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Open-label, single-arm study of oral repotrectinib, a next-generation macrocyclic TKI targeting ROS1, ALK, and TRK (NTRK1/2/3) with CNS penetration, in children <12 with ALK/ROS1/NTRK-altered advanced malignancies (dose-finding) and adolescents/young adults (12–25) with NTRK fusion–positive (TKI-naïve or pretreated) or ROS1-altered advanced solid tumors/ALCL. Eligible patients require measurable disease and prior progression/intolerance or lack of standard therapy; endpoints include safety/PK in pediatrics and confirmed ORR by BICR in expansion cohorts.

ClinicalTrials.gov ID: NCT04094610

TAGGED: A Phase 2 Study Using Low Dose/Metronomic Trabectedin, Gemcitabine, and Dacarbazine as 2nd/3rd/4th Line Therapy for Advanced Soft Tissue Sarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with previously treated, locally advanced or metastatic leiomyosarcoma receive a metronomic regimen of trabectedin (DNA minor-groove binder affecting transcription/repair), gemcitabine (nucleoside analog), and dacarbazine (alkylating agent) on Days 1 and 8 of 21-day cycles. Single-arm study aims to assess disease control and tolerability as later-line therapy, treating until progression or toxicity for up to 1 year.

ClinicalTrials.gov ID: NCT04535271

A Randomized Study Comparing the Efficacy of the Combination of Doxorubicin and the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF to Doxorubicin Alone as First-line Therapy in Patients With Metastatic Leiomyosarcoma

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Metastatic, high-grade (FNCLCC 2–3) leiomyosarcoma patients (ECOG 0–1) without prior systemic therapy for advanced disease are randomized to doxorubicin alone vs doxorubicin plus L19TNF, an investigational antibody–cytokine fusion that targets ED-B fibronectin to deliver TNFα to tumor vasculature and enhance chemotherapy effect. Extensive cardiac exclusions apply; primary endpoint is PFS.

ClinicalTrials.gov ID: NCT03420014

Phase I Trial of TURALIO (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor (TGCT)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolls children and young adults (3–35 years) with refractory/recurrent solid tumors (including CNS tumors, NF1-associated plexiform neurofibromas/MPNST, TGCT) or refractory AML/ALL to receive oral pexidartinib daily in 28-day cycles. Pexidartinib is a small-molecule inhibitor of CSF1R (with KIT and FLT3 activity) targeting tumor-associated macrophages and relevant oncogenic kinases.

ClinicalTrials.gov ID: NCT02390752

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Relapsed/refractory pediatric and young adult sarcomas (osteosarcoma, Ewing, rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue; ages 2–40) receive gemcitabine/docetaxel plus off‑the‑shelf, ex vivo expanded TGFβ‑imprinted universal donor NK cells designed to resist TGFβ-mediated suppression in the tumor microenvironment. NK infusions are given on day 12 of 21‑day cycles (up to 6 NK doses within 8 chemotherapy cycles) with safety and 6‑month PFS assessed.

ClinicalTrials.gov ID: NCT05634369

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-CD19CD20-ALLO1 in Subjects With Selected Relapsed/Refractory B Cell Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with relapsed/refractory aggressive B‑cell lymphomas (DLBCL, high‑grade B‑cell lymphoma, PMBCL, transformed FL/FL3B) after prior anti‑CD20/anthracycline therapy—including those previously treated with CD19‑directed therapy or autologous CAR‑T—receive a single infusion of P‑CD19CD20‑ALLO1 after cyclophosphamide/fludarabine lymphodepletion. P‑CD19CD20‑ALLO1 is an off‑the‑shelf allogeneic dual‑target (CD19/CD20) CAR‑T engineered to reduce alloreactivity and HLA‑I expression with an inducible rimiducid safety switch.

ClinicalTrials.gov ID: NCT06014762

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic prostate adenocarcinoma (ECOG 0–1) post–second-generation AR therapy and typically post-taxane (or ineligible/refusing), with PARP inhibitor exposure if BRCA1/2-mutated, receive oral RO7656594 (GDC-2992), a heterobifunctional androgen receptor antagonist/degrader via cereblon-mediated proteasomal degradation. Dose escalation and expansion assess safety, PK, and preliminary activity, excluding prior AR degrader exposure and untreated CNS disease.

ClinicalTrials.gov ID: NCT05800665

A Phase 1 Study of EP31670, a Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Enrolling adults with ECOG 0–1 who have selected relapsed/refractory cancers: solid tumors (e.g., post–docetaxel/AR-targeted mCRPC or metastatic/unresectable NUT carcinoma) and hematologic malignancies including CMML and intermediate/high-risk myelofibrosis after JAK inhibitor; stable treated brain mets allowed. Investigational therapy is EP31670 (NEO2734), an oral first-in-class dual BET and CBP/p300 inhibitor given intermittently as monotherapy (solid tumors/CMML) or combined with ruxolitinib or momelotinib in myelofibrosis.

ClinicalTrials.gov ID: NCT05488548

A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with metastatic rare genitourinary cancers across multiple histologic cohorts (e.g., small cell/neuroendocrine bladder, variant urothelial, penile, sarcomatoid/unclassified RCC, collecting duct, renal medullary, urethral; including a bone-only GU cohort), with up to two prior lines allowed (cohort-specific exceptions. Patients receive cabozantinib (MET/VEGFR2/AXL multi-kinase inhibitor) plus nivolumab (PD-1) and ipilimumab (CTLA-4) for up to 2 years.

ClinicalTrials.gov ID: NCT03866382

Open Label Phase II Trial of Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) and Known Amplifications or Activating Mutations in Gene Targets of Cabozantinib or Liver Metastases Who Have Received Prior Anti-Androgen Therapy

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with mCRPC who have either measurable liver metastases or molecular alterations in cabozantinib targets (e.g., MET, AXL, VEGFR1–3, RET, KIT, FLT3, TRKB, TIE2) after prior next‑generation antiandrogen therapy; excludes prior cabozantinib. Single‑arm cabozantinib monotherapy (oral multikinase inhibitor of MET/VEGFR/AXL and others) given with ongoing LHRH therapy until progression or toxicity.

ClinicalTrials.gov ID: NCT04631744